ESR1 and breast cancer: The development and commercialization of multigene expression‐based assays (eg, Oncotype DX, MammaPrint, Prosigna, etc.)have resulted in a paradigm shift in BC treatment, specifically in the care of estrogen receptor (ER) and progesterone receptor (PR) positive and HER2‐negative early stage BC.37, 38, 39, 40